Jahangir Alam to Humans
This is a "connection" page, showing publications Jahangir Alam has written about Humans.
Connection Strength
0.535
-
Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
Score: 0.062
-
Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe. 2014 Jun; 27:31-3.
Score: 0.044
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
Score: 0.023
-
A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
Score: 0.023
-
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
Score: 0.022
-
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
Score: 0.021
-
Fusobacteria behaving badly: Masquerading strains of strictly anaerobic Escherichiacoli misidentified due to the deletion of the hemB gene. Anaerobe. 2023 Feb; 79:102682.
Score: 0.020
-
Isolation and characterisation of carbapenem-resistant Pseudomonas aeruginosa from hospital environments in tertiary care hospitals in Dhaka, Bangladesh. J Glob Antimicrob Resist. 2022 09; 30:31-37.
Score: 0.019
-
Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
Score: 0.018
-
Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
Score: 0.018
-
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
Score: 0.017
-
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
Score: 0.017
-
PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
Score: 0.017
-
Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother. 2019 12 20; 64(1).
Score: 0.016
-
Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
Score: 0.016
-
Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis. 2019 05 17; 68(11):1887-1893.
Score: 0.016
-
Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
Score: 0.015
-
Accelerate PhenoTestTM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Ann Pharmacother. 2018 08; 52(8):754-762.
Score: 0.014
-
Acquisition of Clostridium difficile Colonization and Infection After Transfer From a Veterans Affairs Hospital to an Affiliated Long-Term Care Facility. Infect Control Hosp Epidemiol. 2017 Sep; 38(9):1070-1076.
Score: 0.014
-
Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
Score: 0.014
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
Score: 0.013
-
Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of Clostridium difficile. Arch Microbiol. 2017 Mar; 199(2):317-323.
Score: 0.013
-
Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
Score: 0.013
-
A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
Score: 0.013
-
Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
Score: 0.013
-
In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
Score: 0.012
-
Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology. J Clin Microbiol. 2015 Apr; 53(4):1192-7.
Score: 0.012
-
Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis. 2013 Dec; 77(4):324-6.
Score: 0.011
-
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb; 68(2):438-43.
Score: 0.010